Last reviewed · How we verify
Habitual prostaglandin monotherapy
Habitual prostaglandin monotherapy is a Small molecule drug developed by Alcon Research. It is currently FDA-approved. Also known as: Latanoprost, Travoprost, Bimatoprost, Tafluprost.
At a glance
| Generic name | Habitual prostaglandin monotherapy |
|---|---|
| Also known as | Latanoprost, Travoprost, Bimatoprost, Tafluprost |
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Habitual prostaglandin monotherapy CI brief — competitive landscape report
- Habitual prostaglandin monotherapy updates RSS · CI watch RSS
- Alcon Research portfolio CI
Frequently asked questions about Habitual prostaglandin monotherapy
What is Habitual prostaglandin monotherapy?
Habitual prostaglandin monotherapy is a Small molecule drug developed by Alcon Research.
Who makes Habitual prostaglandin monotherapy?
Habitual prostaglandin monotherapy is developed and marketed by Alcon Research (see full Alcon Research pipeline at /company/alcon-research).
Is Habitual prostaglandin monotherapy also known as anything else?
Habitual prostaglandin monotherapy is also known as Latanoprost, Travoprost, Bimatoprost, Tafluprost.
What development phase is Habitual prostaglandin monotherapy in?
Habitual prostaglandin monotherapy is FDA-approved (marketed).
Related
- Manufacturer: Alcon Research — full pipeline
- Also known as: Latanoprost, Travoprost, Bimatoprost, Tafluprost